- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bullous pemphigoid tied to increased risk of CVD, all-cause mortality: JAMA
Taiwan: Findings from a recent study in the journal JAMA Dermatology suggest that patients with bullous pemphigoid (BP) are at a 5-fold increased risk of CVD mortality. This was seen particularly in patients without underlying cardiovascular disease (CVD) or hypertension or those without prior corticosteroid or diuretic use.
The role of bullous pemphigoid in CVD mortality remains controversial and there is a dearth of data on the analyses of causes of death among patients with BP based on individual data. Considering this, Wan-Chieh Shen, Department of Dermatology, China Medical University Hospital, Taichung City, Taiwan, and colleagues aimed to evaluate the risk of all-cause mortality, CVD mortality, and cancer mortality in patients with BP in a cohort study.
The study identified patients with a diagnosis of and treatment for BP at a tertiary medical center in central Taiwan between January 1, 2007, and December 31, 2017. Patients without BP were controls and were individually matched to cases in the ratio of 4:1 according to age, sex, and date of the dermatology clinic visit. Data analysis was done from March 6, 2019, to April 2, 2021. Of 252 patients with BP and 1008 matched control patients (N = 1260), 685 (54.4%) were men and the median age was 78.0 years.
Using typical direct immunofluorescence findings or clinically with typical clinical presentation, positive findings of an anti–basement membrane zone antibody test, and corticosteroid use for at least 28 cumulative days, the researchers confirmed the pathological presence of bullous pemphigoid.
The main outcome measure was mortality outcomes confirmed by the National Death Registry.
Following were the study's key findings:
- Patients with BP had higher CVD mortality at 1 year (7.9% vs 13 1.3%), 3 years (11.1% vs 2.4%), and 5 years (12.3% vs 39 3.9%) compared with matched control patients.
- After adjusting for potential confounding variables, patients with BP had a 5-fold higher risk of CVD mortality at 1 year (hazard ratio [HR], 5.29), 3 years (HR, 5.79), and 5 years (HR, 4.95).
- Subgroup analyses revealed that the CVD mortality risk associated with BP was higher in patients without a history of hypertension (HR, 7.28) or CVD (HR, 6.59) and in patients without prior diuretic use (HR, 5.75) compared with matched control patients.
- In addition, all-cause mortality associated with BP was higher in patients without prior corticosteroid use than in control patients (HR 5.65).
"Our findings suggest that BP is associated with a 5-fold higher risk of CVD mortality, particularly in patients without underlying hypertension or CVD or those without prior corticosteroid or diuretic use," the authors wrote.
"Future studies should investigate the benefits of routine monitoring and timely management of CVD symptoms and signs in patients with BP," they concluded.
Reference:
Shen W, Chiang H, Chen P, Lin Y, Kuo C, Wu P. Risk of All-Cause Mortality, Cardiovascular Disease Mortality, and Cancer Mortality in Patients With Bullous Pemphigoid. JAMA Dermatol. Published online December 29, 2021. doi:10.1001/jamadermatol.2021.5125
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751